Clopidogrel Response in Acute Ischemic Stroke. The Bochumer CRISP Study (Bo-CRISP)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Saskia Meves, Ruhr University of Bochum
ClinicalTrials.gov Identifier:
NCT01843361
First received: April 26, 2013
Last updated: NA
Last verified: April 2013
History: No changes posted
  Purpose

The aim of this study was to determine the prevalence rate and risk factors for chemical laboratory clopidogrel low-response (CLR) in the acute phase after an ischemic stroke.


Condition
Ischemic Stroke

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Prevalence of Low Response to Clopidogrel in Patients After Acute Ischemic Stroke.

Resource links provided by NLM:


Further study details as provided by Ruhr University of Bochum:

Primary Outcome Measures:
  • Result of platelet function test [ Time Frame: one day ] [ Designated as safety issue: No ]
    Aggregometry result of antiplatelet therapy


Enrollment: 159
Study Start Date: July 2010
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
acute ischemic stroke
Determing cardiovascular risk factors or medication on clopidogrel response rates after an acute ischemic stroke

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with an acute ischemic stroke admitted to our stroke unit and treated with clopidogrel

Criteria

Inclusion Criteria:

  • acute ischemic stroke
  • admittance to stroke unit
  • clopidogrel medication

Exclusion Criteria:

  • no consent
  • prior bleeding disorders
  • severe liver disorders
  • current gastrointestinal disorders
  • congestive heart failure
  • life-threatening malignancies
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01843361

Locations
Germany
Department of Neurology, Ruhr University Bochum
Bochum, Germany, 44791
Sponsors and Collaborators
Ruhr University of Bochum
Investigators
Principal Investigator: Saskia H Meves, MD Ruhr University Bochum, Department of Neurology
  More Information

Publications:
Responsible Party: Saskia Meves, MD, Ruhr University of Bochum
ClinicalTrials.gov Identifier: NCT01843361     History of Changes
Other Study ID Numbers: Meves-clopi-01
Study First Received: April 26, 2013
Last Updated: April 26, 2013
Health Authority: Germany: Ethics Commission

Keywords provided by Ruhr University of Bochum:
Stroke
Clopidogrel
Aggregometry
Antiplatelet therapy
Platelet function tests

Additional relevant MeSH terms:
Ischemia
Stroke
Cerebral Infarction
Pathologic Processes
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Brain Infarction
Brain Ischemia
Clopidogrel
Platelet Aggregation Inhibitors
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on April 14, 2014